RVMD Live signals | Maximize Profits with Getagraph.com

BUY 3860 min ago

@ $38.69

Issued: 31 May 2024 @ 12:06

Return: -0.93%

Previous signal: May 31 - 09:30

Previous signal: Sell

Return: 0.47 %

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):
Our systems believe the stock currently is overvalued by 0.20% compare to its pairs and should correct downwards.

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers...

Stats
Today's Volume	1.07M
Average Volume	1.42M
Market Cap	6.32B
EPS	$0 ( 2024-05-08 )
Next earnings date	( $0 ) 2024-08-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-9.98
ATR14	$1.355 (3.54%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-21	Cislini Jeff	Sell	700	Common Stock
2024-05-21	Cislini Jeff	Sell	800	Common Stock
2024-05-03	Anders Jack	Buy	10 000	Common Stock
2024-05-03	Anders Jack	Sell	10 000	Common Stock
2024-05-03	Anders Jack	Sell	10 000	Stock Option (Right to Buy)

INSIDER POWER
72.88
Last 99 transactions
Buy: 5 398 428 \| Sell: 780 101

Correlation (AI algo v.1.1b): Overvalued: -0.20% $38.25 paired level. (The Algo Track The Changes Of The Most Correlated Stocks In Realtime And Give An Instant Update)

Volume Correlation

Long: 0.92 (very strong)

Short: -0.90 (very strong negative)

Signal:(45) Neutral

Revolution Medicines Inc Correlation

10 Most Positive Correlations
NKTR	0.94
VCTR	0.936
GDST	0.934
BCSA	0.928
FRLA	0.925
GGAL	0.923
PAYS	0.923
IVCB	0.923
SMTC	0.922
BOCN	0.92

10 Most Negative Correlations
LIQT	-0.929
ALLR	-0.928
SSYS	-0.927
SIRI	-0.927
WNEB	-0.922
INTC	-0.92
GLPG	-0.919
INTZ	-0.919
JACK	-0.917
MBIO	-0.916

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Revolution Medicines Inc Correlation - Currency/Commodity

0.73
( moderate )

0.66
( moderate )

0.00
( neutral )

0.75
( moderate )

0.02
( neutral )

-0.40
( neutral )

Revolution Medicines Inc Financials

Annual	2023
Revenue:	$11.58M
Gross Profit:	$2.27M (19.61 %)
EPS:	$-3.86

FY	2023
Revenue:	$11.58M
Gross Profit:	$2.27M (19.61 %)
EPS:	$-3.86

FY	2022
Revenue:	$35.38M
Gross Profit:	$25.72M (72.71 %)
EPS:	$-3.08

FY	2021
Revenue:	$29.39M
Gross Profit:	$29.39M (100.00 %)
EPS:	$-2.57

Financial Reports:

No articles found.

Revolution Medicines Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Revolution Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.